<DOC>
	<DOCNO>NCT01932177</DOCNO>
	<brief_summary>EVESOR multiparameter phase I trial aim determine safety different dos dose schedule everolimus combination sorafenib well recommended dos &amp; dose schedule phase 2 trial adult patient advance solid tumor .</brief_summary>
	<brief_title>EVESOR : Phase 1 Trial Everolimus Sorafenib</brief_title>
	<detailed_description>The present phase I trial aim determine safety different dos dose schedule everolimus combination sorafenib well recommended dos &amp; dose schedule phase 2 trial adult patient advance solid tumor .</detailed_description>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients solid tumor ( breast adenocarcinoma , colorectal adenocarcinoma , renal cell carcinoma , gastric oesophageal adenocarcinoma , pancreatic cancer , hepatocellular carcinoma , ovarian Fallopian tube adenocarcinoma , primary peritoneal carcinoma , endometrial cervix cancer , nonsmall cell lung carcinoma , melanoma , thyroid carcinoma ) resistant amenable standard treatment Patients must measurable disease , define least one lesion accurately measure least one dimension ( long diameter record ) &gt; 20 mm conventional technique &gt; 10 mm spiral CT scan . Patients must assessable primary metastatic lesion use dynamic contrast enhance ultrasound Patients must willing two tumor biopsy perform ( one study start one study treatment ) , unless medically contraindicate . No previous treatment sorafenib everolimus . Patients may previously treat one experimental drug : sorafenib everolimus . No limitation prior therapy . However , must least 4 week interval initiation study treatment prior radiotherapy systemic therapy , 6 week last regimen include BCNU mitomycin C. Males female age &gt; 18 year . Life expectancy great 12 week . ECOG performance status ≤ 2 ( Karnofsky &gt; 70 % ; see Appendix A ) . Patients must normal organ marrow function . Patients must able swallow medication . Pregnancy Testing . Women childbearing potential require negative serum pregnancy test within 1014 day within 24 hour prior first dose either drug ( serum urine ) . Ability understand willingness sign write informed consent document . Patient without legal protection measure health coverage . Previous treatment sorafenib everolimus . Patients may receive investigational agent . Patients know brain metastasis exclude clinical trial . History allergic reaction attribute compound similar chemical biologic composition everolimus sorafenib agent use study . Patients take medication narrow therapeutic index metabolize cytochrome P450 ( CYP450 ) , include warfarin sodium ( Coumadin® ) ineligible . Patients take concurrent medication strong inducers/inhibitors CYP3A4 switch alternative medication minimize potential risk . If patient switch alternative medication , ineligible participate study . A list prohibit CYP3A4 inducer inhibitor provide Appendix D. Patients malabsorption syndrome condition would interfere intestinal absorption . Patients serologically positive Hepatitis A , B C , form hepatitis cirrhosis ineligible , except patient hepatocellular carcinoma . Patients hepatocellular carcinoma Child Pugh B C score . Patients uncontrolled hypocalcemia , hypomagnesemia , hyponatremia , hypophosphatemia hypokalemia define less low limit normal institution , despite adequate electrolyte supplementation exclude study . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia chronic , stable atrial fibrillation , psychiatric illness/social situation would limit compliance study requirement . HIVpositive patient combination antiretroviral therapy ineligible potential pharmacokinetic interaction everolimus . Cardiovascular : Patients QTc ≥ 470 mSec , measure ECG use Bazett 's formula male female ineligible . Patients recover side effect previous systemic anticancer therapy ≤ CTCAE Grade 2 prior first dose combination .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Everolimus ; Sorafenib ; Phase 1 trial ; Solid tumor</keyword>
</DOC>